Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123933) titled 'A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-IL-22BP mRNA in Patients with Advanced Malignant Solid Tumors' on May 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: West China Hospital
Condition:
Advanced or metastatic solid tumors
Intervention:
25µg Dose Group:Non-cationic peptide-IL-22BP mRNA formulation, 25µg, intratumoral injection, once weekly for 5 doses
50µg Dose Group:Non-cationic peptide-IL-22BP mRNA formulation, 50µg, intratumoral injection, once weekly for 5 doses
Recruitment Status...